Lifecore Biomedical earns FCPA declination for voluntary self-disclosure
By Kyle Brasseur2023-11-17T18:11:00
Pharmaceuticals company Lifecore Biomedical won’t face prosecution for apparent violations of the Foreign Corrupt Practices Act after satisfying multiple factors of the Department of Justice’s (DOJ) recently updated voluntary self-disclosure policy.
Lifecore’s legal representatives received a declination letter from the DOJ on Thursday, despite the agency finding evidence employees and agents of Lifecore’s former subsidiary Yucatan Foods engaged in bribes paid to Mexican government officials to secure a wastewater discharge permit.
Lifecore agreed to disgorge approximately $406,000 believed to be financial benefit attributable to the alleged bribery conduct.